JP2009235073A5 - - Google Patents

Download PDF

Info

Publication number
JP2009235073A5
JP2009235073A5 JP2009112258A JP2009112258A JP2009235073A5 JP 2009235073 A5 JP2009235073 A5 JP 2009235073A5 JP 2009112258 A JP2009112258 A JP 2009112258A JP 2009112258 A JP2009112258 A JP 2009112258A JP 2009235073 A5 JP2009235073 A5 JP 2009235073A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
polysorbate
sodium starch
starch glycolate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009112258A
Other languages
English (en)
Japanese (ja)
Other versions
JP5054061B2 (ja
JP2009235073A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009235073A publication Critical patent/JP2009235073A/ja
Publication of JP2009235073A5 publication Critical patent/JP2009235073A5/ja
Application granted granted Critical
Publication of JP5054061B2 publication Critical patent/JP5054061B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009112258A 2005-09-12 2009-05-01 ピリミジン−スルファミドを含む安定な医薬組成物 Active JP5054061B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/009775 2005-09-12
EP2005009775 2005-09-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008529767A Division JP4955685B2 (ja) 2005-09-12 2006-09-11 ピリミジン−スルファミドを含む安定な医薬組成物

Publications (3)

Publication Number Publication Date
JP2009235073A JP2009235073A (ja) 2009-10-15
JP2009235073A5 true JP2009235073A5 (https=) 2012-03-29
JP5054061B2 JP5054061B2 (ja) 2012-10-24

Family

ID=37865339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008529767A Active JP4955685B2 (ja) 2005-09-12 2006-09-11 ピリミジン−スルファミドを含む安定な医薬組成物
JP2009112258A Active JP5054061B2 (ja) 2005-09-12 2009-05-01 ピリミジン−スルファミドを含む安定な医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008529767A Active JP4955685B2 (ja) 2005-09-12 2006-09-11 ピリミジン−スルファミドを含む安定な医薬組成物

Country Status (23)

Country Link
US (6) US20080233188A1 (https=)
EP (2) EP1928409B1 (https=)
JP (2) JP4955685B2 (https=)
KR (1) KR101313395B1 (https=)
CN (1) CN101262847B (https=)
AU (1) AU2006290309B2 (https=)
BR (1) BRPI0615898B8 (https=)
CA (1) CA2621273C (https=)
CY (1) CY1113395T1 (https=)
DK (1) DK1928409T3 (https=)
ES (1) ES2393117T3 (https=)
HR (1) HRP20120957T1 (https=)
IL (1) IL190072A (https=)
MY (1) MY151003A (https=)
NO (1) NO341325B1 (https=)
NZ (1) NZ567188A (https=)
PL (1) PL1928409T3 (https=)
PT (1) PT1928409E (https=)
RU (1) RU2424805C2 (https=)
SI (1) SI1928409T1 (https=)
TW (1) TWI323661B (https=)
WO (1) WO2007031933A2 (https=)
ZA (1) ZA200802947B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
ES2543280T3 (es) * 2009-08-10 2015-08-17 Board Of Regents, The University Of Texas System Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico
JP5714600B2 (ja) 2009-12-18 2015-05-07 フリースランドカンピナ・ネーデルランド・ホールディング・ビー.ブイ.FrieslandCampina Nederland Holding B.V. 共加工された錠用賦形剤混合物、その調製及び使用
IT1403248B1 (it) * 2010-11-12 2013-10-17 Scharper Therapeutics Srl Composizione per il trattamento di disfunzioni degli apparati fonatorio ed olfattorio
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
US20170158645A1 (en) * 2014-07-15 2017-06-08 Olon S.P.A. Amorphous form and new crystalline forms of macitentan
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
CN105388244B (zh) * 2015-12-10 2017-03-08 合肥久诺医药科技有限公司 一种马西替坦有关物质的高效液相色谱分析方法
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
CA3123990A1 (en) 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020277546B2 (en) 2019-05-22 2025-07-03 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of pyrimidine sulfonamide compound and preparation method therefor
MX2022000267A (es) * 2019-07-05 2022-02-03 Tecnimede Sociedade Tecnico Medicinal Sa Composiciones comprimidas de macitentan, metodos y usos de las mismas.
CN114728002A (zh) 2019-11-29 2022-07-08 埃科特莱茵药品有限公司 治疗肺动脉高血压的方法
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
TW202317119A (zh) * 2021-06-11 2023-05-01 瑞士商艾克泰聯製藥有限公司 用於口服投予之分散錠
EP4392024A1 (en) 2021-08-25 2024-07-03 Basf Se Direct tableting auxiliary composition
TR2021013983A1 (tr) * 2021-09-07 2023-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Masi̇tentan i̇çeren bi̇r kapsül formülasyonu
EP4154873A1 (en) 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
WO1997022595A1 (en) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
JPH103525A (ja) 1996-06-14 1998-01-06 Dainippon Printing Co Ltd Icカード、命令コード格納方法及び命令コード実行方法
AR017426A1 (es) 1997-12-08 2001-09-05 Smithkline Beecham Corp Sal de monoargininilo del acido (e)-3-[1-n-butil-5-[2-(2-carboxifenil)metoxi-4-clorofenil]-1h-pirazol-4-il]-2-[(5-metoxi-2,3-dihidrobenzofuran-6-il)metil]-prop-2-enoico, composicion farmaceutica que la contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
CA2322315C (en) 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US20040062803A1 (en) * 1999-12-22 2004-04-01 Hedden David B. Sustained-release formulation of a cyclooxygenase-2 inhibitor
HUP0203935A3 (en) * 1999-12-31 2006-02-28 Encysive Pharmaceuticals Inc H Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP2001335469A (ja) 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ ファーマシューティカル インダストリーズ リミティド カルベジロール
WO2002043704A1 (fr) 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition a solubilite ou absorbabilite orale amelioree
IL156315A0 (en) 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
HU229403B1 (en) * 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
JP3930290B2 (ja) 2001-09-12 2007-06-13 富士フイルム株式会社 熱現像感光材料及びそれを用いた熱現像方法
KR20030041577A (ko) 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
WO2003057166A2 (en) * 2002-01-07 2003-07-17 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
KR100698982B1 (ko) 2002-02-11 2007-03-26 화이자 인코포레이티드 Pde4 억제제로서 유용한 니코틴아미드 유도체
KR20100090726A (ko) * 2002-02-26 2010-08-16 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
US7625887B2 (en) 2003-01-28 2009-12-01 Takeda Pharmaceutical Company Limited Receptor agonists
HRP20050675A2 (en) 2003-02-25 2005-10-31 Eli Lilly And Company Crystalline non-solavated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
EP1697382A4 (en) 2003-12-10 2008-11-05 Activbiotics Inc ANALOGUES OF RIFAMYCIN AND USES THEREOF
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
EP2670405B1 (en) 2011-02-04 2015-09-02 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme

Similar Documents

Publication Publication Date Title
JP2009235073A5 (https=)
JP5714492B2 (ja) 粒状体、それらの調製方法、およびそれらを含む医薬品
JP2014167026A5 (https=)
TWI407978B (zh) 濕粒狀藥物之製備方法
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
HRP20151383T1 (hr) Farmaceutski pripravci koji sadrže nilotinib ili njegovu sol
CN101327213B (zh) 厄贝沙坦氢氯噻嗪药用组合物及其制备方法
JP5714600B2 (ja) 共加工された錠用賦形剤混合物、その調製及び使用
JP2014237658A5 (https=)
JP5991968B2 (ja) トルバプタン固形分散剤及びその製造方法
TWI700100B (zh) 用於口服投藥之包含依澤替米貝(ezetimibe)及羅舒伐他汀(rosuvastatin)的複合調配物及其製備方法
CN101822674B (zh) 一种伊潘立酮药物组合物及其制备方法
JP2006514100A5 (https=)
JP5173794B2 (ja) Src/abl阻害剤
WO2020070147A1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
JP6302802B2 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法
CN104254321A (zh) 稳定性提高的药物制剂
JP5575114B2 (ja) シュウ酸エスシタロプラムを含む粒状物
CN104800184B (zh) 琥珀酸呋罗曲坦缓释剂片
JP2009501214A (ja) クロピドグレルビスルファートを含有する薬学的組成物
CN103989652A (zh) 酒石酸美托洛尔缓释制剂及其制备方法
WO2016166733A1 (en) A process for preparing a pharmaceutical composition comprising rivaroxaban
CN105534980B (zh) 瑞格列奈盐酸二甲双胍的药物组合物及其制剂工艺
CN102988316A (zh) 依非韦伦片及其制备方法
KR101817714B1 (ko) 발사르탄을 포함하는 경구용 고형 제제